News

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…

9 months ago

electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has…

9 months ago

aTyr Pharma to Participate in April Investor Conferences

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in…

9 months ago

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

9 months ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick…

9 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…

9 months ago

Aveanna Healthcare Holdings Announces Agreement to Acquire Thrive Skilled Pediatric Care

ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused…

9 months ago

Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare…

9 months ago

Repeat: LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics

Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access…

9 months ago

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution…

9 months ago